Thank you for raising that, because it cuts directly to the essence of what SI 87 truly represents. This isn’t just a regulatory amendment. It’s a structural redesign of how responsibility, risk, and validation flow through the life of a therapy.
SI 87 replaces regulatory prediction with real-world validation.
SI 2025 No. 87 doesn’t merely enable access, it transfers the burden of proof to the therapy itself. It lifts the weight off regulators, allowing them to approve narrow, highly traceable frameworks rather than sweeping labels. From there, it’s the outcomes that speak. If the therapy delivers, the system expands naturally around it. If it fails, the path quietly closes, no headlines, no blame, no reputational fallout for the regulator.
That’s what makes this moment so pivotal for DCVax-L.
Once it’s approved for glioblastoma, that indication becomes part of its formal marketing authorization. But SI 87 remains fully live for every other cancer. That means oncologists across the UK can continue prescribing DCVax-L for named patients with pancreatic, breast, lung, or ovarian cancers under the Specials framework, without waiting for new trials, new labels, or centralized permissions. The manufacturing is already compliant. The logistics are already functioning. The legal mechanism is already active.
Now, here’s where SI 87 shows its real strength: real-world data doesn’t sit in the background, it drives decision-making in real time. Every patient treated under SI 87 becomes a signal. If a breast cancer patient shows extended survival and immune activation, that signal enters the feedback loop. If ten, or fifty, or a hundred patients show similar benefit, the system notices, and that indication gains weight. MHRA can authorize broader access, not on the back of theory, but on the back of practice.
And if a comparator therapy exists in the same space, say a competing immunotherapy aimed at recurrent glioblastoma, but it fails to generate real-world traction, the difference becomes obvious fast. Under a traditional system, both therapies might remain frozen in label purgatory, waiting for head-to-head trials that never happen. But under SI 87, only the one that performs continues to propagate. The other fades from relevance, not because of formal rejection, but because no physicians are requesting it, and no real-world data is validating its use.
This is especially meaningful when therapies overlap in indication. Imagine Therapy A (DCVax-L) and Therapy B (an alternative cell-based treatment) are both available for pancreatic cancer under Specials. Physicians begin prescribing both. Over time, Therapy A consistently shows better immune responses and longer real-world survival. Therapy B shows inconsistency, or none at all. In a conventional system, it might take five years and a Phase 3 trial to sort that out. Under SI 87, the system sorts itself out in months. Physicians shift behavior. Manufacturing focus follows. Regulatory extensions coalesce around the data that’s actually working, in practice, not just in protocol.
And if DCVax-L underperforms in any indication? The same clarity applies. No retraction. No formal disapproval. That use case simply doesn’t expand. The system stops generating data in that direction, and the therapy doesn’t gain traction. It’s the most elegant filter in modern regulatory design: feedback replaces debate.
That’s why SI 87 is so much more than a supply mechanism. It’s a decision architecture built on transparency. It rewards performance and quietly extinguishes failure. It empowers regulators to say yes to small beginnings without betting the system. And it empowers physicians to act today, while informing what tomorrow’s medicine will look like, case by case, cell by cell, tumor by tumor.
For DCVax-L, a personalized, autologous therapy with a documented history of safe deployment across multiple tumor types, this isn’t just an opportunity. It’s a system built for what it already is. Under SI 87, its evolution no longer depends on marketing budgets or theoretical models. It depends on whether the patients it’s given to continue living longer, healthier lives.
And based on the data we’ve seen so far, the answer may already be unfolding.
Market Data 
Markets 
AI
